Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
SLE is an autoimmune condition characterized by varied symptoms and multiple organ involvement, making it a complex disease, which is difficult to manage. Moreover, challenges in clinical trial design and in understanding potential market for SLE therapies often impede drug development, leading to high failure rates of pipeline agents. To date, Benlysta is the only approved biologic for SLE, which caters to a specific SLE population, leaving high unmet need in the SLE space. Pharmaceutical companies have identified the hidden commercial opportunity in this area and, currently, SLE pipeline has several agents in late-phase and many more in early-phase development. The SLE Disease Landscape and Forecast offers detailed insights into current medical practices, key unmet needs, and new developments in SLE space, along with an analysis of opportunities and obstacles faced by emerging agents.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Approximately 30 country-specific interviews with rheumatologists and nephrologists.
Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and lupus nephritis).
Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.
Emerging therapies: Phase II: 20 drugs; Phase III: 6 drugs; Coverage of 7 select preclinical and Phase I products.